Zealand Pharma Introduces Long-Term Incentive Plans for 2025
In a significant move to foster growth and align interests, Zealand Pharma A/S, a renowned biotechnology company, has announced its long-term incentive programs for 2025. These plans are designed specifically for the Board of Directors, Corporate Management, and employees, reflecting the company's commitment to incentivizing exceptional performance and talent retention.
Details of the Long-Term Incentive Program
The new incentive programs, part of Zealand Pharma’s remuneration policy, aim to enhance performance and align the goals of its workforce with the expectations of shareholders. The initiative follows the guidelines established during the company’s last annual general meeting.
Incentives Awarded
Under the new long-term incentive plan, Zealand Pharma has allocated a number of restricted share units (RSUs) and performance share units (PSUs) to different groups:
- 29,169 RSUs have been awarded to the Board of Directors.
- 96,788 PSUs and RSUs awarded to Corporate Management.
- 18,502 RSUs have been awarded to US employees.
- 128,519 RSUs distributed among employees in Denmark, excluding Corporate Management members.
By implementing the LTIP, Zealand Pharma strives to align itself with peers in the biotech industry in Europe and the U.S., focusing on attracting and retaining top talent while ensuring that corporate and employee objectives are closely linked.
Adjustments to Awards
The number of granted RSUs and PSUs remains flexible, as adjustments may occur in response to significant changes in the company’s capital structure or other major corporate events. This ensures that the awards remain relevant and meaningful.
Specifics for Board Members
Board members who also participate in various committees may receive additional grants of RSUs. These grants are included within the total mentioned earlier and are subject to vesting conditions that span from the announcement date until the annual general meeting in 2028. Importantly, total RSU grants for any individual Board member cannot exceed specified limits, ensuring a fair compensation structure.
Vesting and Holding Requirements
RSUs for Board members will vest in stages across three years, with a holding requirement of 200% of the annual RSU grant value. This provision fosters alignment between the interests of Board members and shareholders, encouraging long-term commitment to the company's vision.
Incentive Structure for Corporate Management
Members of Zealand Pharma’s Corporate Management are eligible for annual grants of PSUs and RSUs. PSUs are awarded free of charge based on the achievement of performance targets, emphasizing share performance against industry benchmarks.
Goals for Performance-Based Incentives
The PSUs can vest at varying rates based on how well predefined market-based goals are fulfilled, with potential payouts ranging between 0% to 150% over a three-year period. The RSUs for Corporate Management mirror the vesting schedule of the Board’s RSUs, promoting a consistent approach across the organization.
Incentives for US Employees and Employees in Denmark
The RSU grants for U.S. employees follow a similar vesting schedule, ensuring that employees receive shares at no cost, contingent upon their ongoing employment. The projected market value of these grants underscores the commitment Zealand Pharma has toward its workforce.
For employees in Denmark, RSUs awarded will vest after a three-year period, allowing employees to benefit from the company's growth while fostering a sense of ownership. The total estimated fair market value of these grants highlights Zealand Pharma’s substantial investment in its employees.
About Zealand Pharma A/S
Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S is dedicated to the innovative development of peptide-based medicines. With several drug candidates successfully advancing into clinical trials, the company has made notable partnerships with leading pharmaceutical companies. Zealand Pharma continually strives to enhance healthcare through groundbreaking treatments.
Frequently Asked Questions
What is the purpose of Zealand Pharma's incentive programs?
The programs aim to align the interests of the Board, management, and employees with the shareholders, ensuring focus on long-term performance.
Who is eligible for the long-term incentive plans?
Eligible participants include members of the Board of Directors, Corporate Management, and employees based in the US and Denmark.
What types of awards are included in the incentive programs?
Awards include restricted share units (RSUs) and performance share units (PSUs), which provide a pathway to ownership in the company.
How do the vesting conditions work for the RSUs?
RSUs typically vest over three years, with specific schedules varying depending on the participant's role and location within Zealand Pharma.
What is Zealand Pharma's focus as a biotechnology company?
Zealand Pharma specializes in discovering and developing innovative peptide-based medicines aimed at addressing unmet medical needs.
